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Background: To investigate whether 2 cardiac troponins [conventional troponin-T(cTnT) and high sensitive
troponin-T(hsTnT)] combined with simplified pulmonary embolism severity index (sPESI), or either test alone are
useful for predicting 30-day mortality and 6 months adverse outcomes in patients with normotensive pulmonary
embolism(PE).
Methods: The prospective study included 121 consecutive patients with normotensive PE confirmed by
computerized tomographic(CT) pulmonary angiography. The primary end point of the study was the 30-day
all-cause mortality. The secondary end point included the 180-day all-cause mortality, the nonfatal symptomatic
recurrent PE, or the nonfatal major bleeding.
Results: Overall, 16 (13.2%) out of 121 patients died during the first month of follow up. The predefined hsTnT
cutoff value of 0.014 ng/mL combined with a sPESI ≥1 'point(s) were the most significant predictor for 30-day
mortality [OR: 27.6 (95% CI: 3.5–217) in the univariate analysis. Alone, sPESI ≥1 point(s) had the highest negative
predictive value for both 30-day all-cause mortality and 6-months adverse outcomes,100% and 91% respectively.
Conclusions: The hsTnT assay combined with the sPESI may provide better predictive information than the cTnT
assay for early death of PE patients. Low sPESI (0 points) may be used for identifying the outpatient treatment for
PE patients and biomarker levels seem to be unnecessary for risk stratification in these patients.
Keywords: Prognosis, Pulmonary embolism, Risk scores, TroponinsBackground
Hemodynamic parameters, including systemic pressure
and heart rate, and associated comorbidities such as ma-
lignancy, heart failure, or pulmonary diseases, are import-
ant prognostic factors in patients with pulmonary
embolism(PE) at hospital admission [1-3]. Several models
have been used to determine the prognosis of PE [4-6].
The Pulmonary Embolism Severity Index(PESI) is one of
the validated scores used on admission for estimating the
30-day mortality [7]. Currently, European Society of
Cardiology(ESC) guidelines recommend a risk stratifica-
tion according to the presence of hypotension/shock, right
ventricular dysfunction (e.g. echocardiography, spiral* Correspondence: savasozsu@gmail.com
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reproduction in any medium, provided the orcomputed tomography, or brain natriuretic peptide
testing) or myocardial injury (e.g. cardiac troponin T or I
testing) [8]. In addition, clinical scores have been used to
predict adverse outcomes in acute PE regardless of im-
aging or biomarkers [9].
Laboratory biomarkers, particularly cardiac troponins,
have been shown to identify patients with a high risk for
mortality and an unfavourable prognosis during the
acute phase of PE [10]. A very low amount of troponin
can be detected in the blood of the general population
with currently available highly sensitive assays and these
assays have been reported to produce measures that
relate to adverse cardiovascular outcomes [8,11,12].
Elevated troponin levels have been reported in various
chronic diseases apart from acute myocardial infarctions,
including diabetes and chronic renal disease [10,12].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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assays of cardiac troponin levels, including conventional
troponin-T(cTnT) and highly sensitive troponin-T
(hsTnT) combined with the simplified PESI(sPESI) im-
proves the prediction of 30-day short term and 6 months
long term clinical outcomes for PE patients. We further
aimed to determine whether a combination of these
tools is capable of providing important additive prognos-
tic knowledge and particularly whether it provides a
practical method for the determination of low-risk pa-
tients more easily than either test alone.
Methods
Study design
Prospectively the study enrolled 121 consecutive patients
with normotensive acute PE. The study was approved by
the local ethical committee and written informed con-
sent was obtained from all patients.
Patients and settings
All diagnoses in PE patients were confirmed by contrast-
enhanced computerized tomographic pulmonary angiog-
raphy. The diagnosis of PE was based on the clinical
probability and a positive (≥500 μg/L) D-dimer ELISA
test [13,14]. D-dimer test was requested in case of low
clinical probability only. The records of all patients diag-
nosed in our hospital were analyzed on admission. PE
patients with shock or hypotension (high risk: defined by
the ESC as a systolic blood pressure of 90 mmHg or a
pressure drop of ≥ 40 mm Hg for 15 min if not caused
by new onset arrhythmia) [8] were excluded from the
study.
We determined test characteristics of the sPESI and of
the two different cardiac troponin assays’ (cTnT and
hsTnT) in their prognostic role for predicting the 30-day
outcome (mortality, nonfatal recurrent venous thrombo-
embolism, or nonfatal major bleeding) and 180-day
mortality. The sPESI was calculated giving one point
for the presence of every of the following parameters:
(1) age > 80 years; (2) having a cancer; (3) history of chronic
cardiac or pulmonary disease; (4) heart rate > 110 bpm;
(5) systolic blood pressure 90 to 100 mm Hg; and (6)
arterial oxyhemoglobin saturation <90% measured at
the time of PE diagnosis [11]. Missing data were con-
sidered to be normal. Patients were divided in two
groups, one at a low-risk (0 points) and the other at a
high-risk (≥ 1 point[s]).
Echocardiographic examination
All patients were examined by two-dimensional, pulse-
wave Doppler echocardiography within the first 24 hours
after a diagnosis of PE, using a Vivid 7 (GE Vingmed
Ultrasound, Horten, Norway) with a 2.5-MHz transducer.
The transthoracic echocardiography (TTE) examinationsperformed by an experienced echocardiographer were
blinded to the results of biochemical assays.
Right ventricular dysfunction(RVD) was defined as dilata-
tion of the right ventricle (end-diastolic diameter > 30 mm
from the parasternal view or a right/left ventricular
diameter ratio ≥ 1.0 from the subcostal or apical view),
with hypokinesis of the right ventricular free wall (any
view), or a tricuspid systolic valve > 30 mm-Hg from
the apical or subcostal 4-chamber view [15]. The echo-
cardiographic readers were blinded to the results of the
patient data.
PE-related mortality was defined as death caused by
right ventricular insufficiency or recurrent PE in the ab-
sence of an alternative diagnosis (for example, terminal
cancer). A sudden or unexpected death was considered
as a possible fatal PE in a patient.Study outcomes
The primary end point of the study was the adverse 30-day
outcome, defined as death from any cause. Secondary end
points were 1) nonfatal recurrent venous thromboembol-
ism, 2) nonfatal major bleeding, 3) all-cause mortality within
a 6-month follow-up period. The long-term (6-month)
status of patients who had been discharged from the
hospital was followed by an outpatient visit or by a tele-
phone interview with the patient or his/her treating
physician.
Nonfatal bleeding events were classified as major if they
were overt and 1) occurred in a critical organ (e.g. intra-
cranial, intraocular, or retroperitoneal hemorrhage), 2)
were associated with a drop in the hemoglobin level of
2.0 g/dL or more, 3) required a transfusion of 2 units of
blood or more [16].
Patients with symptoms or signs of recurrent PE were
assessed with objective tests. Recurrent PE was diag-
nosed by the presence of a new intraluminal filling
defect or an extension of a previous filling defect on
computed tomography pulmonary angiography.Biochemical analysis
Venous blood samples were collected on admission.
Troponin-T levels were determined by a quantitative
electrochemiluminescence assay (Elecsys 2010; Roche,
Mannheim, Germany, cut-off value <0.010 ng/ml) on admis-
sion. Samples for hsTroponin-T measures were immediately
centrifuged, frozen and stored at -80°C. hsTroponin-T levels
were defined by quantitative electrochemiluminescence
immunoassays (Elecsys 2010 analyzer, Roche Diagnostics,
Mannheim, Germany) with a cut-off value ≥ 0.014 ng/mL).
A positive troponin test result was defined as a troponin level
above the manufacturers assay threshold for the diagnosis of
myocardial injury.
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The Kolmogorov-Smirnov test was used to assess a nor-
mal distribution of continuous variables. Data character-
ized by a normal distribution were expressed as mean
values and standard deviation. Parameters without such
distribution were expressed as median with the range.
Student’s test (normal distribution) or Mann-Whitney’s
(non-normal distribution) test was used for comparing
the two groups. Discrete variables were compared using
the Fisher exact test (chi-square test). Sensitivity, specifi-
city, positive predictive value, negative predictive value
and accuracy were calculated according to standard for-
mulae. The prognostic relevance of the hsTnT or cTnT
levels, and of the sPESI, with regard to 30-day outcomesTable 1 Characteristic features of patients included in the stu
Demographic factors All pa
Male sex 52
% 43
Median age (25th to 75th percentile) 70 (55
Age > 80 years-(n) % 13
11
Clinical findings
Median pulse (25th to 75th percentile) 90 (80
Pulse > 110 beats/min-(n) % 30
25
Median (25th to 75th percentile) SBP 120 (1
SBP < 100 mm Hg-(n) % 14
12












cTn-T≥0.01 ng/mL -(n) % 50
41
hsTn-T≥0.014 ng/mL-(n) % 66
55
Data are presented as median (interquartile range) and % value.
CHF, congestive heart failure; COPD, chronic obstructive lung disease; NS, not signif
simplified pulmonary embolism severity index.was estimated by using a logistic regression analysis.
Odds ratios (OR) and the corresponding 95% confidence
intervals were calculated. P < 0.05 was considered statis-
tically significant. Data were analyzed using SPSS statis-
tical software.Results
The patients’ characteristics are summarized in Table 1.
The median age was 70 years, ranging from 21 to 104
(25th–75th percentile: 55-76) years, and 52 (43%) were
males. The most frequent presenting symptom was dys-
pnea (75%), chest pain or pleuritic pain (49%), hemoptysis
(16%), and syncope (14%). The risk factors for PE includedy
tients Death (any cause) at 30 days p
No Yes
(n = 105) (n = 16)
45 7 NS
43 44
-76) 70 (54-75) 77 (69-85) 0.003
7 6 NS
7 38
-108) 88 (80-100) 120 (89-129) 0.001
21 9 0.004
20 56

















icant; RVD, right ventricular dysfunction; SBP, systolic blood pressure; sPESI,
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unspecified, more rare, causes (16%).
The median hsTnT level was 0.016, ranging from
0.003 to 0.56 ng/mL (25th–75th percentile, 0.005-0.037).
A total of 66(55%) patients had hsTn–T levels ≥0.014.
The median cTnT level was 0.01 ranging from to 0.01-
0.39, (25th–75th percentile, 0.01-0.027).
A transthoracic echocardiogram was evaluated in 113
patients (93%). Out of these, 53 (47%) were diagnosed
with RVD. Out of 53 patients with RVD, 68% had
hsTnT levels ≥0.014. while 57% had cTnT levels ≥0.01
(p = 0.003, and p = 0.001 respectively).
The sPESI classified 76 patients (62.8%) in the high-
risk group (≥ 1 point[s]). Patients with a sPESI high risk
presented with a positive cTnT level (48%, 37 pts) and a
positive hsTnT level (68.4%, 52 pts) (p=0.033, and
p<0.001, respectively).30-day mortality
Out of the 121 study patients, 16 (13%) died within the
first month after diagnosis. In six of them (38%) the
cause of death was directly related to the PE episode,
whereas other deaths were caused by cancer (31%; 5 out
of 16 deaths), pneumonia (12.5%; 2 out of 16 deaths),
and other diseases (19%, 3 out of 16 deaths).
All the 14 patients with a low sPESI had positive
hsTnT levels and 13 out of them had positive cTnT
levels. None of these patients had adverse events.
As shown in Table 2, alone sPESI ≥ 1 point(s) had a
higher sensitivity, and a higher negative predictive value
for predicting a 30-day mortality in the present study.
None of the patients with hsTnT levels < 0.014 and a
sPESI < 1, or with cTnT levels < 0.014 and a sPESI < 1
(n = 31, 26%) or with cTnT levels < 0.01 and sPESI <1
(n = 33, 27%) died during the study period. Overall, the
risk assessment based on a positive hsTnT level (OR
12.4, 95% CI 1.5–99.3; p = 0.018) maintained its prog-
nostic value for a 30-day mortality when adjusted for the
sPESI (OR: 9.3, 95%CI 1.1–75.4; p = 0.036).
Overall, the risk assessment based on a positive cTnT





sPESI ≥ 1 point(s) 100 (76-100) 4
hsTn-T ≥ 0.014 ng/mL 94 (68-100) 5
cTn-T ≥ 0.01 ng/mL 81 (54-95) 6
hsTnT ≥ 0.014 ng/mL+ sPESI ≥ 1 point(s) 94 (68-10) 6
cTnT ≥ 0.01+ sPESI ≥ 1 point(s) 81 (54-95) 7
RVD on echocardiography 19 (1-32) 9
CI, confidence interval; RVD, Right ventricula r dysfunction; sPESI, simplified Pulmonprognostic value for a 30-day mortality when adjusted
for a sPESI (OR 6.5, 95% CI 1.7–25.2 p=0.007).
Combination model
We investigated the combination of troponins and the
sPESI with regard to risk stratification of PE. Upon
univariate analysis, hsTnT levels ≥14 ng/mL plus a
sPESI ≥ 1 point(s), which represents the high risk PE
patients was associated with a 27.6-fold (95% CI: 3.5-
217.0, p = 0.002) increased risk of 30-day mortality
(Table 3). However multivariate analysis of these parame-
ters was not statistically significant (data not shown).
The 30-days mortality rate rose from 0% to 0.8% in
patients with sPESI ≥ 1 or hsTnT ≥ 0.014 ng/mL, and
further to 12.4% in those with sPESI ≥ 1 and hsTnT ≥
0.014 ng/mL (p < 0.001; Figure 1).
The 30-days mortality rate rose from 0% to 2.5% in pa-
tients with sPESI≥1 or cTnT levels≥0.01, and further to
10.7% in those with sPESI ≥1 and hsTnT ≥0.014 ng/mL
(p < 0.001; Figure 2).
sPESI and hs-Tn-T for prediction of 6-month outcome
Overall, 28 patients (21.1%) reached the secondary end
point including nonfatal recurrent venous thrombo-
embolism (n = 3), nonfatal major bleeding (n = 3) and
all-cause mortality within a 6-month period.
During the follow-up period, a total of 22 deaths (18%
of the all patients) was recorded. Out of these, 16 (13%)
were due to the initial PE event (all within the first 30
days), and 1 (1%) to fatal recurrent PE (only one oc-
curred after day 30). Also, 5 deaths (4%) were due to a
malignancy. Out of 55 patients with hsTnT <0.014 ng/mL
on admission, 3 (5.5%) died; of 45 patients with a sPESI
of 0, one (2.2%) died; of 72 patients with cTnT level
<0.01 on admission, 6 (9%) died. Alone sPESI ≥ 1 point(s)
has the highest negative predictive value and sensitivity for
the long-term adverse outcomes (Table 4).
Discussion
There are three main conclusions that follow from the
present results. Firstly, the sPESI is more useful for




value, % (95% CI)
Positive predictive
value, % (95% CI)
3 (33-53) 100 (90-100) 21 (13-32)
1 (42-61) 98 (89-100) 23 (14-35)
5 (55-74) 96 (87-99) 26 (15-41)
5 (55-74) 99 (91-100) 29 (18-43)
7 (68-85) 96 (89-99) 35 (21-53)
5 (85-99) 57 (47-67) 77 (46-94)
ary Embolism Severity Index.
Table 3 Predictors of 30-day mortality (univariate
analysis)
OR 95% CI P
sPESI ≥ 1 point(s) 12.7 1.6-98.9 NS
RVD 5.6 1.5-21.0 0.011
hsTnT ≥ 14 pg/mL 4.0 1.4-11.2 0.009
cTnT ≥ 001 2.8 1.5-5.4 0.002
hsTnT ≥ 14 pg/mL+ sPESI ≥ 1 point(s) 27.6 3.5-217.0 0.002
cTnT ≥ 001+ sPESI ≥ 1 point(s) 14.6 3.8-55.6 <0.001
OR, odds ratio; RVD, Right ventricular dysfunction; sPESI, simplified Pulmonary
Embolism Severity Index.
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a sPESI ≥ 1 may be used for the short term mortality
risk. Thirdly, sPESI ≥ 1 showed the high negative pre-
dictive value (100%) for 30-day mortality but PE patients
had various clinical presentations leading to different
prognostic and therapeutic approaches. Accurate risk
stratification with precise diagnostic tools is of crucial
importance.
Right ventricular dysfunction on echocardiography/
computed tomography as well as cardiac markers, in-
cluding troponins and clinical scores, are important
tools for accurate risk stratification. There is only one
study comparing the sPESI with any troponins(includingFigure 1 Frequency of an adverse 30-day mortality according to base
troponin T assay; sPESI, simplified PulmonaryEmbolism Severity Index.hsTnT) levels, but this study population was composed
of patients with massive PE [17]. Another study only
compared the prognostic role of the hsTnT assay and of
the sPESI [18]. Thus, comparisons of 2 cardiac troponins
(hsTnT and cTnT) combined with the sPESI or alone
are limited in the literature.
In our study three patients in the group with negative
cTnT levels died in the early period compared to only
one patient who died among the groups with negative
hsTnT levels. The negative predictive value for the sPESI
was 100% for a 30-day mortality. We agree with Lankeit
et al. who found a 100% NPV of PE for the 30-day mor-
tality [18]. In addition, no patient in the group with a
combination of negative hsTnT levels and sPESI < 1
died. As a result it was found that, although the negative
hsTnT level had a similar performance as the low sPESI
for predicting adverse outcomes, it was obviously super-
ior to the cTnT assay.
Mortality of PE has been defined to be <1% in patients
without RVD on echocardiography or computerized
tomography, and also with no elevations in biomarkers
[9]. However, advanced age and associated comorbidities
may increase the mortality for PE. Therefore, the
addition of the sPESI to the biomarkers and to RVD
may provide more accurate risk stratification of PE. Any
patient with PE and one of the following factors (ageline hsTnT levels and the sPESI. hsTnT indicates high-sensitivity
Figure 2 Frequency of an adverse 30-day mortality according to baseline cTnT levels and the sPESI. cTnT indicates conventional troponin
T assay; sPESI, simplified PulmonaryEmbolism Severity Index.
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ence of cancer) has been classified as high risk patient,
thus causing an overestimation of the risk stratification
for these PE patients. Therefore, specificity of the high
risk sPESI is lower than that of cardiac biomarkers and
of right ventricular dysfunction on echocardiography for
PE mortality [17,19]. The specificity of echocardiography
decreases from 78% to 17–22% in PE patients with ac-
companying comorbidities [8]. However, a favourable
prognosis of PE can be easily estimated when the sPESI
is low. According to the sPESI model the 30-day overall
mortality in the low risk group has been reported to be
between 0% and 2% [16,17]. Fourteen patients with a





sPESI ≥ 1 point(s) 86 (66-95) 4
hsTn-T ≥ 0.014 ng/mL 79 (56-91) 5
cTn-T ≥ 0.01 ng/mL 68 (48-83) 6
hsTnT ≥ 0.014 ng/mL+ sPESI ≥ 1 point(s) 75 (55-86) 6
cTnT ≥ 0.01+ sPESI ≥ 1 point(s) 64 (44-81) 8
CI, confidence interval; sPESI, simplified Pulmonary Embolism Severity Index.However, none of these PE patients with positive
ahsTnT level had an adverse event. Relatively to the
good prognosis for PE patients with a low sPESI, the
hsTnT assay may be an unnecessary marker, especially
in those patients who are in the low sPESI group.
Interestingly, in the present study the 30-day mortality
was found to be 0.8 for patients that only had an
hsTnT ≥ 0.014 ng/mL or a sPESI ≥ 1. Lankeit et al. found
a 3.6% adverse outcome in the same patients population.
However, one third of their study population had renal
failure which could be associated with positive troponin
values in that study [18]. Therefore combination models
may provide much more information about the prognosis




value, % (95% CI)
Positive predictive
value, % (95% CI)
4 (34-55) 91 (78-97) 31 (22-43)
3 (42-63) 89 (77-95) 33 (23-46)
7 (56-76) 87 (77-94) 38 (25-53)
7 (56-76) 90 (80-95) 40 (27-55)
0 (70-87) 88 (79-94) 49 (32-65)
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risk patients with PE may improve the quality of life, and
provide reductions of cost [20].
Combinations of prognostic tools including multiple
biomarker assay, biomarker plus right ventricular dys-
function (both on echocardiography/tomography) and
PESI (not simplified) plus shock index were found to be
more predictive than biomarkers and PESI only for the
risk stratification of PE patients [21-24]. In patients with
hsTnT level ≥ 0.014 ng/mL plus a sPESI ≥ 1 there was a
94% risk of 30 day all-mortality and a mortality rate
12.4%. Lankeit et al. reported the 30 day adverse out-
come as 10.4% in the same group [18]. In SWIVTER
study it was found that patients with a high sPESI plus
any positive troponin test (conventional troponin T or I,
highly sensitive troponin T) had a mortality rate of
10.3% [17]. Moreover, the mortality rate was found to be
15.4% in a group where the PESI (not simplified) was
combined with troponin-I in another study [25]. It re-
mains unclear whether thrombolysis may improve the
early and long-term clinical outcomes of selected
normotensive patients with a high risk score and/or with
biomarker positivity. The PEITHO trial, a prospective,
multicenter, international, randomized, double-blind study
is currently comparing thrombolysis with tenecteplasevs
placebo in a normotensive patient group with confirmed
PE (NCT00639743).
Of course there are some limitations in the present
study. Firstly, our study population is relatively small,
and secondly, we did not study hsTnT testing at the 3rd
hour of admission which has 100% negative predictive
value for the exclusion of myocardial infarction. In
addition, when interpreting our results it should also be
considered that no autopsy was performed. The third
concern may be related to the recurrent PE which was
diagnosed by the presence of a new intraluminal filling
defect or an extension of a previous filling defect on
computed tomography pulmonary angiography. Be-
cause the whole diagnosis of PE patients was initially
confirmed by contrast-enhanced computerized tomo-
graphic pulmonary angiography in the present study,
we did not use perfusion lung scan which could be
feasible for the recurrent PE and for the follow up of
those PE patients.Conclusion
Although the present study was conducted on a limited
number of patients, the hsTnT assay combined with the
sPESI may provide more predictive information than the
cTnT assay for the prognosis of PE. Particularly, a low
sPESI may be used for the identification of outpatient
treatment options and in these patients biomarker levels
seem to be unnecessary for the prognosis of PE.The study was accepted as a poster by ERS 2012
congress. This study was conducted at Farabi Hospital,
Trabzon, Turkey.
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